Affitech signs license agreement for single-chain antibody technology with Micromet
Affitech AS announced that it has signed an agreement with Micromet AG for a non-exclusive worldwide sub-licensable research license to the joint patent estate of Micromet and Enzon Pharmaceuticals, Inc. in the field of single-chain antibodies (SCA).
Under the terms of the agreement, Affitech will have rights to conduct research involving SCA technology and will have sublicense rights to third parties for the purpose of conducting research, develop or use an SCA product generated by Affitech. No other terms of the agreement were announced.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents

99 million people included in largest global COVID-19 vaccine safety study - Global Vaccine Data Network utilises vast data sets to detect potential vaccine safety signals
Affibody AB provides novel molecular imaging agents for visualizing HER2-expressing cancer
BTG signs agreement with Novacea and KuDOS for AQ4N
To-BBB awarded EUR 1.25 million European FP7 funding to develop treatments for inherited retinal diseases
Galapagos enters into discovery collaboration with Idenix for infectious disease programs
Bayer and Ortho-McNeil, Inc. Outline Phase III Study Program of Oral Factor Xa Inhibitor Rivaroxaban in Chronic Indications - Patient Recruitment for Phase III Clinical Trial to Start in Studies of Oral Anticoagulant in Chronic Indications
AnaSpec and UW TechTransfer Sign Licensing Agreement for Protein Tyrosine Phosphatases
